Journals / Anadolu Kardiyoloji Dergisi / 2014 / Cilt: 14 - Sayı: 3

Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension

Pages
234–238
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined.
📊
Key Findings & Data:Methods: Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively.
💡
Conclusion & Impact:Results: At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: In the present study, left ventricular hypertrophy and serum ghrelin concentration in patients with primary hypertension and effects of angiotensin receptor blocker valsartan on these parameters were determined. Methods: Thirty-seven patients and 30 age and body mass index matched healthy controls were followed up prospectively. Serum ghrelin level was measured by enzyme immunoassay (EIA). Left ventricular mass was determined by transthoracic echocardiography. Left ventricular mass index (LVMI) was calculated by dividing the left ventricular mass to body surface area. All patients were started treatment with oral valsartan 80 mg. Follow-up visits were performed every 4 weeks, and the dosage was doubled in subjects with insufficient blood pressure reduction. At the end of the 12th week all measurements were repeated in the patient group. All data were recorded in the computer using SPSS for Windows software. Mann-Whitney U, Student t, Wilcoxon and t tests were used for statistical analyses. Results: At baseline, mean serum ghrelin level was significantly lower in the patients group (14.9 ng/mL) compared to healthy controls (42.1 ng/mL) (p

🔖

Cite This Article

BAYSAN, O., MERİÇ, C., AYDOĞDU, A., TAŞÇI, İ., DENİZ, F., SERDAR, M., SAĞLAM, K., AZAL, Ö. (2022). Effects of valsartan treatment on serum ghrelin level and left ventricular mass index in patients with untreated primary hypertension. Anadolu Kardiyoloji Dergisi, Cilt: 14 - Sayı: 3, 234–238. https://ajindex.com/articles/436064

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402: 656-60. [CrossRef] 2. Ariyasu H, Takaya K, Tagami T, Ogawa Y, Hosoda K, Akamizu T, et al. Stomach is a major source of circulating ghrelin and feeding state determines plasma ghrelin-like immuno reactivity levels in humans. J Clin Endocrinol Metab 2001; 86: 4753-8. [CrossRef] 3. Volante M, Allia E, Gugliotta P Funaro A, Broglio F, Deghenghi R, et al. Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab 2002; 87: 1300-8. [CrossRef] 4. Dezaki K, Sone H, Yada T. Ghrelin is a physiological regulator of insulin release in pancreatic islets and glucose homeostasis. Pharmacol Ther 2008; 118: 239-49. [CrossRef] 5. Seppo M, Eija K, Sohvi H, Heikki K, Antero K, Olavi U. Low plasma ghrelin is associated with insulin resistance, hypertension, and prevalence of type 2 diabetes. Diabetes 2003; 52: 2546-53. [CrossRef] 6. Matsumura K, Tsuchihashi T, Fujii K, Abe I, Iida M. Central ghrelin modulates sympathetic activity in conscious rabbits. Hypertension 2002; 40: 694-9. [CrossRef] 7. Nagaya N, Kojima M, Uematsu M, Yamagishi M, Hosoda H, Oya H, et al. Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 2001; 280: 1483-7. 8. Nagaya N, Miyatake K, Uematsu M, Oya H, Shimizu W, Hosoda H, et al. Hemodynamic, renal, and hormonal effects of ghrelin infusion in patients with chronic heart failure. J Clin Endocrinol Metab 2001; 86: 5854-9. [CrossRef] 9. Aoki H, Nakata M, Dezaki K, Lu M, Gantulga D, Yamamoto K, et al. Ghrelin counteracts salt-induced hypertension via promoting diuresis and renal nitric oxide production in Dahl rats. Endocr J 2013; 60: 571-81. [CrossRef] 10. Chang L, Ren Y, Liu X, Li WG, Yang J, Geng B, et al. Protective effects of ghrelin on ischemia/reperfusion injury in isolated rat heart. J Cardiovasc Pharmacol 2004; 43: 165-70. [CrossRef] 11. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104: 1430-5. [CrossRef] 12. Wiley KE, Davenport AP Comparison of vasodilators in human internal mammary artery: ghrelin is a potent physiological antagonist of endothelin-1. Br J Pharmacol 2002; 136: 1